Antleron’s Post

Leaders from #AskBio and Shanghai-based Belief BioMed (BBM) earlier this week signed a collaboration agreement that will enable both companies to combine efforts and experience in #GeneTherapy technology to explore potential therapies for diseases that may be treatable using a liver-targeted approach. This strategic collaboration is an excellent example of how we work at AskBio. Collaborating with innovative, like-minded partners with complementary gene therapy expertise enables us to find the best way forward for our pipeline assets and bolster our efforts to advance new therapies for conditions with significant unmet need. #Leadership Jane Zheng, Philip Sin, Dr. Xiao Xiao, Tracy Dowling, Gustavo Pesquin

👁️ Dive into the world of retinitis pigmentosa (RP) with Dr. Reza Rezarei from Cyagen! 🎥 In this insightful video, Dr. Rezarei sheds light on RP, a group of rare inherited disorders causing vision loss. Discover how Cyagen's HUGO-GT model, specifically the B6J-hRHO mice, is revolutionizing gene therapy development for RP. Watch now and join us in our mission to understand and conquer RP! 🧬 #RetinitisPigmentosa #GeneTherapy #Cyagen #HUGOGT #VisionResearch #Research #researchanddevelopment #biotech #biotechnology #sciencecommunication #preclinical #preclinicalresearch

We are proud of our colleagues, Cesar Trigueros, Chief Scientific Officer, Jacob Smith, Head of Technical Development, Thomas Guarinoni (DSP Director) and Eric Vorst (DSP MSAT) for their recent contribution to a groundbreaking study on rAAV purification published on Cell & Gene Therapy Insights magazine. Their work introduces an innovative approach using “Displacement Chromatography for enrichment of rAAV genome-containing capsids using weak organic acid” to improve efficiency and scalability in gene therapy production. Here are some of the highlights: - Simplifying traditional methods, enabling an isocratic elution, and eliminating operational challenges associated with linear salt gradients.  - The new approach replaces complex ultracentrifugation and challenges associated with scale up.  - The method maintains consistent and high product quality across all production scales.    Check out their work here: https://lnkd.in/dpEsHpcK This would not have been possible without the collaboration of: Tamara Zarubica-Zekovic , Paul Greback-Clarke , Eva Graham , Jordan Hobbs , Robert Tikkanen , Hunter Reese , Amith Naik, PhD , Rashmi Bhangale, Ph.D. , Carlos Cruz-Teran , Christian Denis , Mayur Jain #rAAV #CDMO

I get to ask these guys all the tough #CGT market questions next week! Excited to moderate this discussion kicking off our new webinar series on #AdvancedTherapies with Carl Schoellhammer and Merouane Ounadjela Thursday, September 19, 2024 9:00 AM PT - 10:00 AM PT Register Here: https://lnkd.in/gXQwJ7WX At JPM earlier this year, Carl published predictions for #drugdevelopment which we'll revisit in our conversation. In addition to: - Key trends and challenges in Cell & Gene Therapy - Pipeline prioritization and strategic decision-making for product development - How to scale advanced therapies efficiently while reducing costs - Why we’ve invested in this critical area and how it shapes the future of our advanced therapies practice We're just kicking off our Advanced Webinar series so we'll be inviting more industry experts to join the conversation. Let me know who we should include next! #BiotechWeekBoston #CellGeneTherapy #PrecisionMedicine

👏 Congratulations, Somagenetix! 👏 Despite a tough fundraising climate, we're extremely happy for our current project Somagenetix, who managed a successful first closing of its Series A financing round at CHF 10M. The round was led by Vi Partners. Among others, existing investors Schroders Capital, Zürcher Kantonalbank and Verve Ventures also participated to this financing round. The funds will be used to advance its leading gene therapy-candidate, SGX-001, into a clinical trial. SGX-001 is being developed for the treatment of p47 Chronic Granulomatous Disease (CGD). CGDs are a group of inherited #immunodeficiencies with recurrent life-threatening infections. The preclinical development of p47-CGD gene therapy is currently supported by us at Wyss Zurich. ✨ Full press release 👉 https://lnkd.in/ejHcxqjJ #StartupInnovation #BiotechRevolution #GeneTherapyAdvancements #FundraisingSuccess #FinancingRound #BiotechFunding #HealthcareStartups #LifeSciencesInnovation

  Landmark Bio’s Eli Kraus, Yun Chen,Ph.D., Manish Tandon and Gregg Nyberg, demonstrate application of a rapid analytical method in cutting-edge Extracellular Vesicle (EV)-based therapy biomanufacturing. Based on widely available conventional Flow Cytometer configurations, the method development was presented at the ECI Advancing Manufacture of Cell and Gene Therapies Conference in Coronado, CA. Read about the accuracy, precision, and reliable EV quantitation by Flow Cytometry, its benefit, criticality, and limitation in directly supporting clinical EV biomanufacturing platforms. #ExtracellularVesicles #FlowCytometry  

Meet our Cerba Research experts at the upcoming ESGCT Conference. #cell&gene #clinicaltrial #esgct

📣Delighted to announce that our portfolio company, Somagenetix secured a CHF 10 million Series A, led by Vi Partners! Our Managing Partner Diego Braguglia commented: 🎙️ “Vi Partners participation in Somagenetix is an investment in the future of personalized medicine. By harnessing cutting-edge lentiviral gene therapy technologies, Somagenetix is positioning itself at the forefront of innovation that has the potential to transform lives on a global scale. We are proud and excited to support a company that is leading the change towards a healthier tomorrow.” Link to the full article in the comments👇 #venturecapital #lifesciences #genetherapy #phagocytedisorders

𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗲 𝘆𝗼𝘂𝗿 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗲𝗳𝗳𝗶𝗰𝗮𝗰𝘆 𝘄𝗶𝘁𝗵 𝗮𝗻 𝗮𝗴𝗴𝗿𝗲𝗴𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝘄𝗶𝘁𝗵 𝗧𝗘𝗠. Aggregation analysis is vital for enhancing the stability and efficacy of virus-based vaccines and gene therapy products. Our expertise in nanoparticle transmission electron microscopy (hashtag #TEM) enables us to assess aggregation visually and quantitatively—a key factor in product performance. Our experts perform a quantitative aggregation analysis of viral particles on TEM images with the help of our proprietary software, which semi-automatically detects and classifies individual particles and aggregates. At QuTEM (formerly Vironova BioAnalytics), we can use our analytical tools to monitor clusters and aggregates of your sample over time. By leveraging Transmission Electron Microscopy (TEM), we offer precise quantification of individual particles and aggregates, expressed either by total particle count or as a percentage ratio of the sample. #Aggregation analysis can be performed for .e.g. #AAVs (Adeno Associated Virus),#Adenoviral vectors, #LNPs (lipid nanoparticles) etc.

Are you interested in exploring translational pathways, #cell and #gene therapy applications, and challenges surrounding #ATMP manufacturing? ➡️ Register now: https://ow.ly/AiWT50TjOm4 2 weeks lefts to register for our event with the Medical Technologies Innovation Facility (MTIF) at Nottingham Trent University where you will learn how #MTIF and the Cell and Gene Therapy Catapult use their capabilities and assets to advance the #cell and #gene therapy sector. Register today ☝️ #MTIF #CellandGene #ATMP #capabilities